The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations
Abstract
BACKGROUND: Anaplastic thyroid carcinoma (ATC) is the most lethal form of thyroid neoplasia and represents the end stage of thyroid tumor progression. In the current study, genetic alterations in a panel of ATC were profiled to determine the origins of ATC. METHODS: Eight ATC were analyzed for BRAF mutation at codon 599 by using mutant‐allele‐specific polymerase chain reaction (PCR) and DNA sequencing of the PCR‐amplified exon 15. RAS mutation (HRAS, KRAS, and NRAS) at codons 12, 13, and 61 was analyzed by direct sequencing of PCR‐amplified exons 1 and 2 of the RAS gene. RET/PTC rearrangements and p53 mutation were monitored by immunohistochemical (IHC) staining by anti‐RET antibodies and an anti‐p53 mAb, respectively. RESULTS: BRAF was mutated in 5 of the 8 ATCs tested. Histologic examination revealed that 4 of these 5 BRAF‐mutated ATCs contained a PTC component, suggesting that they may be derived from BRAF‐mutated PTC. Of the 3 ATCs with wild‐type BRAF, 2 had spindle cell features; one had follicular neoplastic characteristics mixed with papillary structures. Analysis of RAS mutation revealed only an HRAS mutation at codon 11, due to the transversion of GCC to TCC in one ATC with wild‐type BRAF. This leads to the substitution of valine to serine. IHC analysis of RET/PTC rearrangements revealed no positive staining of RET in any of 8 ATCs, suggesting that these ATCs are not derived from RET/PTC‐ rearranged PTC. In contrast, IHC analysis of p53 mutation revealed that p53 was detected in the nuclei of 5 of 5 BRAF‐mutated ATCs and 2 of 3 ATCs with wild‐type BRAF. p53 staining was present only in anaplastic thyroid tumor cells but not in neighboring papillary thyroid tumor cells. CONCLUSIONS: These results suggest that many ATCs with papillary components are derived from BRAF‐mutated PTC, because of the addition of p53 mutation. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Cited by
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
Kondo, T., Ezzat, S., & Asa, S. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1836 · Cited by 893
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Smallridge, R. C., Marlow, L. A., & Copland, J. A. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0154 · Cited by 390
Riesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Elsheikh, T. M., Asa, S. L., Chan, J. K. C., DeLellis, R. A., Heffess, C. S., LiVolsi, V. A., & Wenig, B. M. (2008) · American Journal of Clinical Pathology · doi:10.1309/ajcpkp2quvn4rccp · Cited by 320
Metadata
- Authors
- Quiros, R. M., Ding, H. G., Gattuso, P., Prinz, R. A., & Xu, X.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-05-03
- Volume
- 103
- Issue
- 11
- Pages
- 2261-2268
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2083294133
- Cited by
- 223
- References
- 2
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.